Phase IIa Study of Redirected Autologous T Cells Engineered to Contain Anti-CD19 Attached to TCRz and 4-Signaling Domains in Patients With Chemotherapy Relapsed or Refractory CD19+ Lymphomas

Clinical trial NCT02030834 · COMPLETED

Trial details

NCT number

NCT02030834

Sponsor

University of Pennsylvania

Status

COMPLETED

Phase

Phase 2

Study type

INTERVENTIONAL

Start date

2014-02-05

Primary completion

2019-09-16

Enrollment

63

View on ClinicalTrials.gov